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Summary 
Chemotactic factors are postulated to direct emigration of lymphocytes from the blood stream 
into sites of inflammation. Members of a family ofchemotactic cytokines, termed chemokines, 
have been shown to attract lymphocytes but efficacy, i.e., the maximal percentage of attracted 
cells, has been low. We have identified a highly efficacious lymphocyte chemotactic activity in 
the supernatants of the murine bone marrow stroma cell line MS-5 which attracts 10-fold more 
lymphocytes in vitro than currently described lymphocyte chemoattractants. Purification of this 
chemotactic activity revealed identity to stromal cell-derived factor 1 (SDF-1).  SDF-1  acts  on 
lymphocytes and monocytes but not neutrophils in vitro and is both a highly efficacious and 
highly potent mononuclear cell attractant in vivo. In addition, SDF-1 induces intracellular ac- 
tin polymerization in lymphocytes, a process that is thought to be a prerequisite for cell motil- 
ity. Since SDF-1 is expressed constitutively in a broad range of tissues it may have a role in im- 
mune  surveillance  and  in  basal  extravasation of lymphocytes and  monocytes rather  than  in 
inflammation. 
L 
Ymphocytes function as the reservoir of immunological 
memory.  In  contrast  to  neutrophils  and  monocytes, 
lymphocytes  may leave  tissues  through  lymphatics,  emi- 
grate from the blood stream into lymphoid and non-lym- 
phoid  tissues,  and  recirculate  multiple  times  during  their 
life history  (for review see reference  1).  Chemoattractants 
are postulated to help direct lymphocyte traffic into sites of 
inflammation and into lymphoid and non-lymphoid tissues 
during recirculation  (1,  2).  The best lymphocyte chemoat- 
tractants identified to date are members of a family of small, 
60 to 80 amino acid chemotactic cytokines termed chemo- 
kines. The chemokines can be divided into two subfamilies, 
the CXC- and the CC-chemokines. The members of each 
subfamily are  more  homologous  to  one  another  than  to 
members of the other subfamily, and differ in the spacing of 
the first two cysteines. The two subfamilies differ in  their 
chromosomal  localization  and  cluster  on  chromosome  4 
(CXC-chemokines)  and  chromosome  17  (CC-chemo- 
kines),  respectively. While  CXC-chemokines,  e.g.,  inter- 
leukin 8 (IL-8), act mostly on neutrophils, members of the 
CC-chemokines, e.g., monocyte chemoattractant protein 1 
(MCP-1) 1, regulated on activation normal T  cell expressed 
1Abbreviations used in this paper: MCP-1, monocyte chemoattractant pro- 
tein 1; MIP-10t, macrophage  inflammatory  protein lce; RANTES, regulated 
on activation normal T cell expressed and secreted; SDF, stromal cell- 
derived factor. 
and secreted (RANTES), and macrophage inflammatory pro- 
tein  lcl  (MIP-lo0, have been shown to exert function  on 
monocytes, eosinophils and lymphocytes (2,  3).  However, 
the efficacy, i.e.,  the percent of attracted ceils,  of lympho- 
cyte  chemoattractants  described  so  far  is  low,  whereas 
chemokines active on monocytes, neutrophils, and eosino- 
phils are highly efficacious (2). 
The bone marrow not only produces precursor and im- 
mature lymphocytes, but  also  harbors  mature  T  lympho- 
cytes. These give rise to graft versus host disease and are an 
important  problem  in  bone  marrow  transplantation.  To 
understand  what  drives  recirculation  of mature  lympho- 
cytes into the bone marrow we screened supernatants from 
bone  marrow  stromal  cells  for  chemotactic  activity.  We 
subsequently identified a lymphocyte chemoattractant pro- 
duced by bone marrow stromal cells and purified it to ho- 
mogeneity.  It is highly  efficacious,  attracting greater than 
10-fold more lymphocytes than currently described chemo- 
attractants.  It stimulates actin polymerization, is  active on 
monocytes and not on neutrophils in vitro, and in vivo is 
both  a  highly  efficacious and  highly  potent  mononuclear 
cell  attractant.  Its  sequence  shows  identity  with  stromal 
cell-derived  factor  (SDF-1)(4-6),  previously  known  to 
augment B  cell proliferation.  SDF-1  shows equidistant se- 
quence  homology  to  CC-  and  CXC-chemokines  and 
strong conservation in evolution that suggest it as a primor- 
dial chemokine.  SDF-1  by contrast to most chemokines is 
constitutively  expressed  in  a  broad  range  of tissues  (4-6) 
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rather than in inflammation. 
Materials  and Methods 
Three-Step Purification of a Lymphocyte Chemoattractant.  Adher- 
ent MS-5 routine bone marrow stromal cells (7) were cultured in 
expanded  surface  roller  bottles  (model  25285-1700;  Coming, 
Coming, NY)  in 150 ml Iscove's modified Dulbecco's medium 
with  10%  FCS  and 2  X  10-5M  2-mercaptoethanol until they 
reached  confluence.  The  medium  was  replaced  with  250  ml 
X-VIVO  serum-free medium  (BioWhittaker,  Walkersville, MD) 
containing 10  mM  Hepes.  Supernatants were  collected and re- 
placed with fresh medium every 5 d for up to five times. Condi- 
tioned medium (1,000 ml) was passed through a 0.22dam filter 
and applied to a 5-ml-HiTrap heparin column (Pharmacia Bio- 
tech,  Uppsala,  Sweden)  on  a  Pharmacia  FPLC  system  using 
FPLC director 1.03 software.  The column was washed with 25 ml 
of 10 mM sodium phosphate, pH 7.3, and eluted with 50 ml of a 
linear gradient of 0.4-2.0 M  NaC1 in 10 mM sodium phosphate, 
pH 7.3.  Active material eluted at 0.8-0.9  M  NaC1  (14 nil) was 
pooled  and diluted with  10  mM sodium phosphate,  pH  7.3,  to 
0.15 M  NaC1,  and applied to a 1 ml SP Sepharose HP cation ex- 
change  column  (Pharmacia  Biotech,  Uppsala,  Sweden)  equili- 
brated with the same buffer, washed with 5 ml of the same buffer, 
and eluted with 40 ml of a linear gradient of 0.1-1.0 M  NaC1 in 
10 mM sodium phosphate, pH 7.3. Active material that eluted at 
~0.52 M  NaC1 (2 ml) was applied to a 4.6 X  150 mm Vydac C4 
reverse-phase HPLC  column (Vydac,  Hesperia,  CA),  equilibrated 
with 0.1%  trifluoroacetic  acid  and eluted with  a  60  ml  0-80% 
acetonitrile gradient in 0.1%  trifluoroacetic acid.  2-ml fractions 
were  lyophilized and resuspended in 100  txl of 10  mM sodium 
phosphate, pH 7.3,  150 mM NaC1 for chemotaxis assays or in 10 
mM sodium phosphate, pH 7.3, for NH2-terminal amino acid se- 
quencing (190  pmol),  amino acid composition, and mass  spec- 
trometry.  Purified protein was  submitted to  automated Edman 
microsequencing on an Applied Biosystems  494A protein sequencer 
(Foster City, CA) using the manufacturer's recommended proto- 
col  (8).  Molecular  weight  was  determined  by  microcapillary 
HPLC/electrospray  ionization/tandem mass  spectrometry  on  a 
Finnigan TSQ7000  triple  quadrupole  mass  spectrometer  (San 
Jose, CA) and by matrix-assisted laser desorption mass spectrome- 
try on a Finnigan Lasermat 2000  (Hemel, England) as described 
previously (9).  Protein concentrations were determined by BCA 
protein assay (Pierce Chem. Co., Rockford, IL). 
Cell Preparation and Chemotaxis Assay.  Human PBL were ob- 
tained from  healthy donors  by erythrocyte  sedimentation with 
6%  Dextran  T500  followed by  Ficoll-Histopaque-1077  (Sigma 
Chem.  Co.,  St.  Louis,  MO)  separation.  Monocytes  were  re- 
moved by two  30-min steps  of plastic adherence  (10).  Human 
neutrophils were prepared as described (11).  Human PBL  (5  X 
105) in 100 ILl RPMI-1640 medium, 0.25% human serum albu- 
min (HSA) were added to the top chamber of a 6.5-mm diame- 
ter, 5-txm pore polycarbonate Transwell  TM  culture insert (Costar, 
Cambridge, MA)  and incubated in duplicate with the  indicated 
concentrations of purified material or dilutions of fractions from 
purification in the bottom chamber for 3  h.  Fractions from the 
heparin, SP Sepharose,  and HPLC columns were diluted 2-fold, 
10- to 50-fold, and 40- to  1,000-fold, respectively, before assay. 
The  chemotaxis assays across  bare filters  and endothelial mono- 
layers cultured on filters were carried out as described previously 
(10,  11),  except cells that transmigrated into the lower chamber 
were vigorously suspended and counted with a FACScan  |  (Bec- 
ton Dickinson, San Jose, CA) for 20 s at 60 Ixl/min, gating on the 
forward and side scatter of the cell type of interest. A  1:20 dilu- 
tion of input PBL was similarly counted. For human monocytes, 
peripheral blood mononuclear cells  (5 ￿  10s), i.e., the cells from 
Ficoll-Histopaque before monocyte depletion, were migrated for 
2  h  through  5-1xm pore  polycarbonate filters  and were  scatter- 
gated on monocytes to exclude lymphocytes. Human neutrophils 
(5  ￿  105) were migrated for  1.5  h  through 3-1xm pore polycar- 
bonate filters.  Murine spleen and bone marrow  cells  were  ob- 
tained from  129  mice  and erythrocytes  were  lysed in NH4C1- 
buffer for 4 min on ice. Spleen cells and bone marrow cells were 
migrated for 3 h and 1.5 h and scatter-gated on lymphocytes and 
neutrophils, respectively. To effectively remove neutrophils and 
monocytes from plastic in the lower chamber a final concentra- 
tion of 5 mM EDTA was added to each well and cells were resus- 
pended vigorously. 
Chemokines.  MCP-1, RANTES, MIP-l~x, IL-lcx, IL2, IL-3, 
IL-4, IL-6, and IL-8 were obtained from Genzyme (Cambridge, 
MA)  and lymphotactin from  Peprotec  (Kocky  Hill,  NJ).  Syn- 
thetic lymphotactin was a kind gift of Dr. Ian Clark-Lewis (Hon- 
son  Centre  for  Cancer  Research,  Adelaide,  Australia).  Murine 
MCP-1/JE  was a kind gift of Dr.  Catherine Ernst (Dana Farber 
Cancer Institute, Boston, MA). 
Actin Polymerization Assay.  Actin  polymerization  was  tested 
as described before (12).  Briefly, human PBL (1.25  X  106/ml) in 
L15 medium at 37~  were incubated with the indicated chemo- 
kines at concentrations that were shown to be optimal in chemo- 
taxis experiments or PMA at  100 ng/ml. At the  indicated time 
points, cells (400 b~l) were added to 100 ILl of a solution at 37~ 
containing 4  X  10 -v  M  FITC-labeled phalloidin,  0.5  mg/ml 
1-c~-lysophosphatidylcholine (both Sigma) and 18% formaldehyde 
in PBS. The fixed cells were subjected to fluorescence flow cy- 
tometry on a FACScan  |  (Becton-Dickinson, San Jose,  CA) and 
the  mean relative fluorescence  of each  sample  determined.  All 
data points are plotted relative to the mean relative fluorescence 
of the sample before addition of chemoattractant. 
Biologic Activity of SDF-1 In Vivo.  C57B1/6 mice were injected 
subcutaneously at a  marked spot  on the  abdomen with  100  ng 
SDF-1 or murine MCP-1/JE in 20 ~1 sterile PBS or PBS alone. 
Injected protein solution was  shown  to  contain <0.004  ng/ml 
LPS by the limulus assay (Sigma).  Mice were sacrificed 18 h after 
injection, injection sites were excised and snap-frozen 5-txm cry- 
osections were  subjected to hematoxylin and eosin staining and 
for immunohistochemistry, sections were pretreated with avidin/ 
biotin blocking reagent (Vector Labs., Burlingame, CA), stained 
with  mAbs  to  Thy-1  (1:10;  PharMingen,  San  Diego,  CA)  or 
MOMA-2  (1:10;  Biosource  International, Camarillo,  CA)  and 
developed with  the  avidin-biotin-Hl:kP method  (DAKO,  Car- 
pinteria,  CA).  Sections  were  counterstained with  hematoxylin. 
No cellular infiltrate was detected in PBS injection sites that were 
sectioned  in  their  entirety.  The  sections  are  representative  of 
three experiments. 
Phylogenetic Analysis.  The  mature  amino  acid  sequences  of 
known chemokines were aligned using the clustal method with a 
PAM250 residue weight table and default settings of gap penalties 
for  pairwise  and multiple alignments of 3  and  10,  respectively 
(Megalign; DNASTAR., Madison, WI). The GenBank accession 
numbers or  reference  for  sequences  used  from  top  to  bottom 
were M31626, Z48479, M57440, X72308 (13), P80075, X77603, 
J04467, M23502, M23503, D00044, M23477, M77747, M21121, 
1102  A Highly Efficacious  Lymphocyte Chemoattractant Figure 1.  HPLC purification and SDS-PAGE of a stromal-derived lymphocyte chemoattractant. Reverse-phase HPLC on a Vydac C4 column was 
the last purification step. Fractions were diluted 40-fold for the chemotaxis assay,  and the background migration of 4.5%, was subtracted. Purified lympho- 
cyte chemoattractant, fraction 21 from the HPLC column (0.5 ~g) was subjected to SDS 15% PAGE and silver staining after no treatment or after treat- 
ment with N-glycanase (N) or O-glycanase (O) from Genzyme according to the manufacturer's instructions. The mass of standards is shown next to the 
gel. An asterisk indicates fractions with chemotactic activity equal to or below background. 
U15607, U23377, U23772, M57506, M17957,J03561,  M36820, 
M36821, J04596, M54995, X78686, M25897, M15254, Y00787, 
M57439, X02530, X72755, D21072, and U16752. 
Results and Discussion 
Purification  of a Highly Efficacious Lymphocyte  Chemoattrac- 
tant.  In  peripheral blood lymphocyte  chemotaxis  assays, 
serum-free conditioned media of three murine bone  mar- 
row stromal cell lines, MS-5 (7), PA-6 (14), and ST-2 (15), 
consistently  attracted  20-50%  of the  input  lymphocytes, 
whereas supernatants from NIH 3T3 fibroblasts showed lit- 
tle  activity.  The  chemotactic  activity was  purified  1,310- 
fold  from  MS-5  conditioned  medium  by sequential  hep- 
arin,  cation exchange,  and reversed-phase HPLC  chroma- 
tography  (Table  1).  The  chemoattractant  activity coeluted 
with  a  single  protein  peak  in  reversed-phase  HPLC  and 
migrated as a  single band in  SDS-PAGE of 8  kD  (Fig.  1). 
We  consistently  obtained  80-90  Ixg  of purified  protein 
from  1,000  ml of conditioned medium. The NH2-terminal 
sequence  of the material was KPVSLSYRXPXRFFE,  with 
smaller amounts of a sequence lacking the first five residues 
of  the  above  sequence,  SYRXPXRFFESHIA.  This  se- 
quence,  and the amino acid composition, showed identity 
with  stromal  cell-derived factor-1  (SDF-1),  a  chemokine 
identified by signal sequence trap cloning (4) and as a factor 
that  augments  IL-7-stimulated pre-B  cell growth  (5).  Ac- 
tivity  of SDF-1  in  chemotaxis  assays  has  not  previously 
Table 1.  Purification  of a Stromal-derived Lymphocyte Chemoattractant 
Chemotactic  Amount of  Specific 
Volume  activity  protein  activity  Purification  Yield 
ml  U  mg  U/mg  -fold  % 
MS-5 supernatant  1000  4000  2720  1.47  1  100 
Heparin HiTrap  72.3  1446  3.11  465  316  36.2 
SP Sepharose HP  4  160  0.236  678  461  4.0 
RP-HPLC  0.2  160  0.083  1930  1310  4.0 
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Chemotactic activity of SDF-1 on human and murine leukocyte subtypes and effect on actin polymerization. (A-E) The indicated human  Figure 2. 
(A-C) or murine (D-E) leukocyte subtypes were subjected to chemotaxis through 5-1*m pore (A, B, and D) or 3-pmi pore (C and E) Transwell  TM  filters 
to the indicated chemoattractant in the lower chamber and the % of input cells that accumulated in the lower chamber was measured. The bars and sym- 
bols show duplicates and mean for one representative experiment of three.  (F) Actin polymerization in human PBL. SDF-1 (1,000 ng/ml), huMCP-1 
(100 ng/ml), huMIP-la (100 ng/ml), and PMA (100 ng/ml) at the indicated optimal concentrations were added to PBL at time 0 and intracellular 
F-actin content in PBL at the indicated times was measured with FITC-phalloidin in permeabilized cells. 
been reported.  Two  alternatively spliced  forms  of SDF-1 
differ in the COOH-terminal  four amino acid residues (4). 
Electrospray and matrix-assisted laser desorption mass spec- 
trometry  gave  a  mass  of 7847.1  +_  0.4  daltons  consistent 
with  that  of 7849.2  daltons predicted  for  SDF-hx  begin- 
ning with the KPVSL sequence and with the COOH-ter- 
minal lysine residue removed by processing.  SDF-1  is not 
glycosylated,  as  shown  by  its  mass  and  lack  of effect  of 
N-glycanase  or  O-glycanase  (Fig.  1),  and  lacks  predicted 
glycosylation sites. 
SDF-I  E~ciently  Attracts Lymphocytes and  Monocytes In 
Vitro.  Purified  SDF-1  was  a  highly  efficacious  lympho- 
cyte  chemoattractant,  attracting 70%  of human peripheral 
blood  lymphocytes  in  filter  chemotaxis  assays  at  optimal 
concentrations  of about  1  I*g/ml  (Fig.  2  A).  Consistent 
with  the  high  percentage  of enfigrating cells,  the  propor- 
tions of CD4 +, CD8 +, CD26 +, CD45RA +, and CD45R,  O + 
T  lymphocyte subsets were similar in the starting and emi- 
grated populations by immunofluorescent flow cytometry. 
The proportions in the starting and emigrating populations 
were  for  CD4  47  and  48%,  for  CD8  24  and  28%,  for 
CD26  64  and  66%,  for  CD45RA  42  and  44%,  and  for 
CD45RO  40 and 43%, respectively. SDF-1  was also an ef- 
ficacious  chemoattractant  and  showed  a  similar  dose- 
response  for  murine  lymphocytes  (Fig.  2  D)  and  human 
monocytes (Fig. 2  B), but was not active on human or mu- 
rine neutrophils  (Fig.  2,  C  and  E).  Chemotaxis  to  SDF-1 
was dependent on a  G~i-coupled receptor.  Pretreatment of 
PBL  with  50  ng/ml of pertussis  toxin inhibited migration 
to  1  Ixg/ml of SDF-1  of 85  +  2.9% of input lymphocytes 
to background levels of 3.2  -+ 0.7%. 
We compared SDF-1  to other lymphocyte chemoattrac- 
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Figure  3.  Transendothelial 
chemotaxis of  human  PBL  to 
SDF-1  and  MCP-1.  Human 
umbilical vein  endothelial cells 
(HUVEC)  cultured on  8-p~m 
pore Transwells  TM  were used in a 
chemotaxis  assay with human 
PBL. One representative experi- 
ment of three is shown. Error ban 
indicate the range of duplicates. 
tants in a range of concentrations previously reported to be 
most active; the greatest migratory response to each and the 
concentration giving the  greatest  response  are  shown  in 
Table 2. MCP-1, RANTES, and MIP-lc~ consistently in- 
duced migration over background, and were more potent 
than SDF-1, i.e., active at lower concentrations, but were 
substantially less effective, attracting only 2-4% of the input 
cells.  Furthermore, the chemotactic index, the ratio of spe- 
cific to background migration is only 1.3- to  2.3-fold for 
MCP-I,  R_ANTES,  and MIP-I& in filter chemotaxis as- 
says.  Fig. 2 A  visualizes this difference in efficacy between 
SDF-1 and proinflammatory chemokines over a broad range 
of  chemokine  concentrations.  Two  different  sources  of 
lymphotactin showed little activity in our assay,  as did dif- 
ferent interleukins (Table 2), basic fibroblast growth factor, 
leukemia inhibitory factor,  transforming growth  factorq3, 
platelet-derived growth factor AA, and granulocyte mono- 
cyte-colony stimulating factor (data not shown). 
SDF-1  was  also  a  highly effective transendothelial che- 
moattractant.  It  attracted  20-30%  of input PBL  (Fig.  3), 
whereas MCP-1, RANTES, and MIP-lc~ attract  1-3% of 
input lymphocytes across endothelium (Fig. 3)  and (3,  10, 
11).  The background in transendothelial chemotaxis assays 
(Fig. 3)  is markedly lower than in filter chemotaxis assays 
(Fig.  2  A),  as  previously noted  (10).  Checkerboard  titra- 
tions demonstrated that SDF-1 stimulated chemotaxis rather 
than random migration in both transendothelial (Table 3) 
and bare filter (not shown) chemotaxis assays. 
SDF- I Induces Actin Polymerization in Lymphocytes.  To mon- 
itor intracellular actin reorganization, a process that is thought 
to  be  a  prerequisite for  cell movement, we  assayed  actin 
polymerization (12). SDF-1  (1,000 ng/ml) induced a tran- 
sient  twofold  increase  in  intracellular  filamentous-actin 
within  15  s in human peripheral lymphocytes (Fig.  2  F). 
Actin polymerization in neutrophils is stimulated by IL-8, 
fMLP, C5a, and LTB4 with the same kinetics (16,  17) but 
to our knowledge an increase in F-actin has not been pre- 
viously observed with chemokines in lymphocytes. Consis- 
tent with  our findings in the  chemotaxis assay,  the  other 
lymphocyte  chemoattractants  stimulated little  actin poly- 
merization. 
Table 2.  Chemotaxis  of Human Peripheral Blood Lymphocytes to 
Optimal  Concentrations of SDF-1,  Interleukins and Previously 
Described Lymphocyte  Chemoattractants 
Migrated lymphocytes  Chemotactic 
above background  index 
% of input +- SD  +_ SD* 
SDF-1  (1,000 ng/ml)  69.2  _+ 8.8  20.3  +  2.1 
hu MCP-1 (100 ng/ml)  3.4 +  0.7  2.3  -+ 0.4 
mu MCP-1/JE (50 ng/n-]l)  1.9 +_ 0.4  1.6 +  0.1 
hu RANTES (100 ng/ml)  2.5  +  0.8  1.5 -+ 0.2 
hu MIP-I(x (10 ng/ml)  2.7  --- 0.2  1.3 --- 0.3 
hu lymphotactin 
(100 ng/ml)  0.4 +  0.1  1.1  +  0.1 
hu IL-lot (10 ng/ml)  -1.4 --- 0.9  0.7  --- 0.1 
hu IL-2 (10 U/ml)  -0.7 _+  1.3  0.9  _+ 0.2 
hu IL-3 (100 U/ml)  -0.3 --_ 1.6  1.0 -+ 0.3 
hu IL-4 (30 U/nil)  -0.8 -+ 1.3  0.8  _+ 0.1 
hu IL-6 (50 ng/ml)  -1.1 --- 1.0  0.9  +  0.2 
hu IL-8 (10 ng/ml)  0.4 _+  1.1  1.1  +  0.2 
*Chemokines and interleukins were assayed over a 1,000-fold concen- 
tration range and results at the optimal concentration are shown. Re- 
sults are mean and SD of three independent experiments. Chemotactic 
index was defined as the ratio between the percentage of cells migrated 
to sample and to medium alone. 
SDF-I  Is  an  Efficacious  and  Potent  Chemoattractant  for 
Mononudear Cells In  Vivo.  Subcutaneous injection of 100 
ng of purified SDF-1  into the skin of C57B1/6 mice elic- 
ited a dense infiltrate of mononuclear cells in the subcuta- 
neous tissue throughout a substantial surrounding area (Fig. 4, 
B and C). Multiple sections failed to reveal any infiltrate at 
PBS injection sites (Fig. 4 A).  Injection of 100 ng of mu- 
fine MCP-1 elicited an infiltrate of far fewer cells that were 
localized  to  the  point  of injection,  and  contained both 
monocytes and neutrophils (Fig. 4 F), in agreement with a 
Table 3.  Checkerboard  Assay qf SDF-1 in Transendothelial 
Chemotaxis* 
SDF-1 concen- 
tration in lower 
chamber 
SDF-1 concentration (ng/ml) in top chamber 
1,000  330  100  0 
ng /ml  Transendothelial migration (%) 
1,000  0.9  _+ 0.2  2.7  _+ 0.1  14.2 _+ 0.3  23.4 -+ 2.3 
330  0.2-+ 0.0  0.2  +  0.0  1.4 +0.1  11.1 +0.2 
100  0.2_+  0.0  0.1  _+ 0.0  0.2_+  0.0  2.8_+0.1 
0  0.1  -0.0  0.1_+0.0  0.1  +0.0  0.1  +0.0 
*Results are representative of three experiments and are expressed as 
percentage of input lymphocytes _+ range of duplicates. 
1105  Bleul et al. Figure 4.  Activity of SDF-1 and MCP-1 in vivo. (A) Skin at the subcutaneous injection site of 20 ~l PBS (10￿  magnification). (/3) Skin at the subcu- 
taneous injection site of 100 ng SDF-1  in 20 ~1 PBS (10X  magnification). A dense cellular infiltrate is visible in the subcutaneous tissue below the pan- 
niculus carnosus. (C-E)  100 ￿  magnification of cellular infiltrate to  100 ng SDF-1. (C) Hematoxylin and eosin staining. (D)  lmmunohistochemical stain- 
ing with mAb Thy-1  (19)  as a marker for T  cells.  About 10%  of the mononuclear cells  were found to be Thy-1  positive.  (E)  Immunohistochemical 
staining with mAb MOMA-2 (20) as a marker for monocytes/macrophages. The majority of mononuclear cells were MOMA-2 positive. (F) Skin at the 
subcutaneous injection site of 100 ng murine MCP-1/JE in 20 ILl PBS, 100￿  magnification, hematoxylin and eosin staining. 
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Figure 5.  A phylogenetic tree of chemokines. The mature amino acid sequences of known chemokines in Swiss-Prot were aligned using the clustal 
method with a PAM250 residue weight table and default settings of gap penalties for pairwise and multiple alignments of 3 and 10, respectively (Mega- 
lign; DNASTAR., Madison, WI). Distances to branch points are proportional to amino acid sequence divergence from predicted ancestral sequences. The 
clustal alignment method grouped the CC-chemokines and the C-chemokine lymphotactin together in the same subfamily. Comparing mature human 
protein sequences, SDF-la is 21 + 4% and 27 -+ 3% (mean + SD) identical to CC- and CXC-chemokines, respectively; for comparison, MCP-1 is 49 + 
19% and 17 + 2% identical and IL-8 is 19 -+ 3% and 35 + 7% identical to other human CC- and CXC-chemokine subfamily members, respectively. 
previous report (18). Less than 1% of the cells infiltrating to 
SDF-1 were neutrophils.  Immunohistochemistry with mAb 
to Thy-1 (19) revealed the presence of up to 10% lympho- 
cytes  (Fig.  4  D)  among a  majority  of monocytes/macro- 
phages  as  demonstrated  by staining  with  mAb MOMA-2 
(20; Fig. 4 E). 
We have shown that SDF-1 exhibits unparalleled efficacy 
as a lymphocyte chemoattractant in vitro and effectively at- 
tracts mononuclear cells in vivo. It attracts ~-,10-fold more 
lymphocytes  than  previously  described  chemoattractants, 
and achieves an efficacy comparable only to that seen pre- 
viously with attractants ofneutrophils, eosinophils, and mono- 
cytes (2).  In vitro SDF-1 is less potent, i.e.,  requires higher 
concentrations for maximal activity, than MCP-1, RANTES, 
and MIP-lc~. However, in vivo SDF-1 is both a highly po- 
tent and highly efficacious chemoattractant for attraction of 
mononuclear cells.  The number of cells  infiltrating  to  100 
ng SDF-1  is far greater than to  100 ng MCP-1  in parallel 
experiments,  and greater than seen in previous in vivo stud- 
ies  to all doses of MCP-1,  MCP-2,  MCP-3,  and RANTES 
(18, 21-23).  It is intriguing to observe the high percentage 
of monocytes  in  the  infiltrate  although  SDF-1  attracts  a 
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similar  percentage  of lymphocytes  and  monocytes  with 
similar dose-response in vitro (Fig. 2, A  and B). This find- 
ing may be due to the higher migratory capability of mono- 
cytes compared to lymphocytes that has been observed in 
different  in vivo models  (24).  Issekutz  and  Issekutz  show 
that  skin  injections  of  zymosan-activated  serum  (ZAS), 
TNF-0q  IFN-~/,  or LPS  in  rats  induce  consistently  more 
than fivefold greater monocyte than lymphocyte accumula- 
tion at all time points tested (24). This is comparable to the 
ratio  of monocyte  to  lymphocyte  emigration  seen  here 
with SDF-1 in vivo. Greater expression of adhesion mole- 
cules,  greater  motility,  or a  lower frequency of exit  from 
the  site  after  entry,  may  favor  greater  accumulation  of 
monocytes  than  lymphocytes  in  vivo,  even  when  the 
strength of the chemoattractive stimulus is comparable. 
The in vivo potency of SDF-1  is remarkable.  SDF-1  is 
highly basic  with  a  predicted  pI  of 10.9  compared to 9.8 
and  9.9  for  IL-8  and  MCP-1,  respectively.  SDF-1  binds 
heparin  with  higher  affinity than  IL-8 or MCP-1  in  that 
elution  from  heparin  Sepharose  requires  800-900  mM 
NaC1, whereas  IL-8 and MCP-1  elute at ~500 mM NaC1 
(3,  25).  Strong binding to glycosaminoglycans may present SDF-1  in  an  effective manner  or  help  retain  it  at sites  of 
production,  and may in part explain its observed potency in 
vivo. 
The  evolutionary and sequence  homology properties  of 
SDF-1  are  unique  among  chemokines.  First,  the  human 
homologue  of SDF-1  (26)has  a  single  conservative Ile to 
Val  substitution  compared  to  the  murine  SDF-1  studied 
here.  This  strong  conservation  (99%  identity)  is  unparal- 
leled  among  chemokines;  for  comparison  MCP-1  and 
RANTES  are  60  and  83%  identical  between  mouse  and 
human.  Second,  based  on  amino  acid  sequence  homolo- 
gies,  SDF-1  is  almost  equally  related/distant  from  both 
CC- and CXC-chemokines  (Fig. 5 and legend). This coin- 
cides with the finding that the human SDF-1  gene is local- 
ized on chromosome  10 while all other known  CXC- and 
CC-chemokines cluster on chromosomes 4 and 17, respec- 
tively (26).  Alignment  of the mature amino acid sequences 
of known  chemokines  generates  a  phylogenetic  tree  that 
confirms  that  the  CC-  and  CXC-chemokines  belong  to 
separate  subfamilies,  and  suggests  that  SDF-1  belongs  to 
neither and forms an outgroup,  SDF-1  is predicted among 
currently  known  chemokines  to  have  diverged  the  least 
from  a  primordial  chemokine  ancestor;  this  is  consistent 
with the high conservation of SDF-1  between species. Be- 
cause of both its functional and predicted phylogenetic dis- 
tinctions  from CC-  and  CXC-chemokines,  SDF-1  is thus 
far  a  unique  chemokine;  whether  it  represents  the  first 
member of a new chemokine  subfamily remains to be de- 
termined, 
SDF-1  is constitutively produced by bone marrow stro- 
real cells, and therefore  could be involved in trafficking of 
lymphocytes  and  monocytes  to  this  site.  Bone  marrow 
stromal cells produce it in large quantities,  with 0.8  b~g/ml 
recovered from cultured cells. Whether SDF-1  plays a spe- 
cial role in bone marrow,  or whether production  is higher 
to compensate for rapid loss through  the fenestrated endo- 
thelium of bone marrow, remains to be determined.  IfSDF-1 
is important in attracting mature lymphocytes to bone  mar- 
row,  antagonism  of this  function  before  harvest  of bone 
marrow for transplantation  could be clinically beneficial. 
SDF-1  may be  of wider  importance.  SDF-1  mRNA  is 
constitutively  expressed in  every tissue  thus  far examined, 
including  heart,  liver, lung, brain,  muscle, spleen,  and kid- 
ney (4, 6, 27), although protein expression has not yet been 
characterized.  Most  other  chemokines  are  only  expressed 
in response to proinflammatory stimuli,  and are thought  to 
regulate  the  emigration  and  activity  of leukocytes  at  in- 
flammatory sites. By contrast,  expression of SDF-1  is unal- 
tered  by inflammatory  stimuli  (27).  Normal  trafficking  of 
lymphocytes  through  tissues  during  immune  surveillance 
requires G protein-coupled receptors (1) but the identity of 
the receptors on lymphocytes and the ligand(s)  remain un- 
characterized.  In the absence of inflammation blood mono- 
cytes  constantly  replace  mononuclear  phagocytes  in  solid 
tissues  maintaining  a  steady  state  by  emigrating  from  the 
blood stream and  differentiating  into  macrophages.  SDF-1 
has a  tissue distribution  that suggests it as a  candidate  for a 
function  in lymphocyte recirculation,  and in basal recruit- 
ment ofmonocytes in normal replenishment and turnover of 
tissue mononuclear phagocytes, rather than in inflammation. 
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